Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | BRD2 | P25440 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.51 |
| ▸ | CSNK1G2 | P78368 | 2/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.51 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10389918 | 0.89 | MAP4K4 (0.59) | ALDH1A1GAABRD4BRD2CREBBP | |
| Hydrochloric Acid SCHEMBL27634975 | 0.89 | BRD4 (0.50) | DHODHALDH1A1KDM4EGAAHTT | |
| SCHEMBL2586835 | 0.87 | KMO (0.59) | ALDH1A1GAABRD4BRD2CREBBP | |
| SCHEMBL76212 | 0.87 | PARP1 (0.65) | ALDH1A1GAAPARP1MAOBNPC1 | |
| SCHEMBL29639739 | 0.87 | PARP1 (0.65) | ALDH1A1GAAPARP1MAOBNPC1 | |
| SCHEMBL4572428 | 0.86 | NPC1 (0.56) | DHODHGAABRD4BRD2CREBBP | |
| SCHEMBL4428711 | 0.86 | MAPT (0.64) | DHODHALDH1A1KDM4EGAAHTT | |
| Fluoride SCHEMBL27643407 | 0.85 | PARP1 (0.63) | ALDH1A1GAAPARP1MAOBNPC1 | |
| SCHEMBL23289047 | 0.85 | DHODH (0.58) | DHODHGAABRD4BRD2CREBBP | |
| SCHEMBL23289052 | 0.85 | DHODH (0.58) | DHODHGAABRD4BRD2CREBBP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019076343-A1 | PD-1/PD-L1 SMALL-MOLECULE INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海长森药业有限公司 | 2019-04-25 | — | — | WO | disclosed |
| US-9969726-B2 | Metabotropic glutamate receptor negative allosteric modulators (NAMS) and uses thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2018-05-15 | — | — | US | disclosed |
| US-20170217951-A1 | Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof | SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE (US) | 2017-08-03 | — | — | US | disclosed |
| EP-2097387-B1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-04 | — | — | EP | disclosed |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | NORTHEASTERN UNIVERSITY (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | NORTHEASTERN UNIVERSITY (US) | 2011-02-17 | — | — | US | disclosed |
| EP-2177518-A1 | Organic compounds | Novartis AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| EP-1833816-B1 | SUBSTITUTED PIPERIDINES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| US-7582658-B2 | Bicyclic compound | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-09-01 | — | — | US | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039874-A1 | MONOACYLGLYCEROL LIPASE INHIBITORS FOR MODULATION OF CANNABINOID ACTIVITY | MGLL, FAAH, FAAH2 | DHODH 1891/4885ALDH1A1 1479/4885KDM4E 1945/4885 |
| US-20170217951-A1 | Metabotropic Glutamate Receptor Negative Allosteric Modulators (NAMS) and Uses Thereof | GRM3, GRM2, GRM1 | DHODH 4420/4885ALDH1A1 4541/4885KDM4E 2181/4885 |
| US-20110071178-A1 | Methods and Compounds for Modulating Cannabinoid Activity | FAAH, FAAH2, CNR2 | DHODH 2168/4885ALDH1A1 1365/4885KDM4E 1921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.